Cargando…

511. Risk Factors for Seeking Medical Care Following Nirmatrelvir-Ritonavir (Paxlovid) Treatment For COVID-19

BACKGROUND: In December 2021, the FDA issued an emergency use authorization (EUA) for nirmatrelvir-ritonavir (Paxlovid). This was based on the randomized placebo-controlled trial data from the EPIC-HR study which showed that high-risk non-hospitalized patients given Paxlovid had an 88.9% reduction i...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bhargava, Ashish, Szpunar, Susan M, Sharma, Mamta, Saravolatz, Louis
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678608/ http://dx.doi.org/10.1093/ofid/ofad500.580

Ejemplares similares

Nirmatrelvir/ritonavir (Paxlovid®): French pharmacovigilance survey 2022
por: Bihan, Kevin, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Generalized use of Nirmatrelvir plus ritonavir (Paxlovid): Raising concerns
por: Sánchez Fabra, David, et al.
Publicado: (2023)

Drug Interaction Between Tacrolimus and Paxlovid (Nirmatrelvir/Ritonavir) in an Adolescent with Inflammatory Bowel Disease
por: Zaarur, Leenoy, et al.
Publicado: (2023)

Tacrolimus Drug–Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin
por: Sindelar, Morganne, et al.
Publicado: (2022)

Paxlovid (Nirmatrelvir/Ritonavir): A new approach to Covid-19 therapy?
por: Hashemian, Seyed Mohammad Reza, et al.
Publicado: (2023)

535. Risk Factors for Seeking Medical Care Following Monoclonal Antibody Treatment For COVID-19
por: MALIK, I S M A I L O, et al.
Publicado: (2023)

314. Six-Month Post-Acute Sequelae of COVID-19: High Self-Reported Morbidity among Women and Younger Adults
por: Bhargava, Ashish, et al.
Publicado: (2021)

Le nirmatrelvir-ritonavir (Paxlovid®), un traitement contre la Covid-19
por: Buxeraud, Jacques, et al.
Publicado: (2022)

Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: de Oliveira, Luciana Mello, et al.
Publicado: (2023)

Response to Comment on “Tacrolimus Drug-Drug Interaction with Nirmatrelvir/Ritonavir (Paxlovid™) Managed with Phenytoin”
por: Sindelar, Morganne, et al.
Publicado: (2023)

528. Matched Retrospective Study, Comparing Molnupiravir to Nirmatrelvir-Ritonavir (Paxlovid) in the Treatment of Mild-Moderate COVID-19 in Immunocompromised Cancer Patients
por: Haddad, Andrea, et al.
Publicado: (2023)

36. Clinical Features of and Risk Factors for 30-day Readmission after an Initial Hospitalization with COVID-19
por: Fukushima, Elisa Akagi, et al.
Publicado: (2021)

Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and Comedications
por: Marzolini, Catia, et al.
Publicado: (2022)

Overview of Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Targeted Therapy and Supportive Care for Lung Cancer
por: Anwar, Kaleem, et al.
Publicado: (2022)

WCN23-0117 PAXLOVID ( NIRMATRELVIR/RITONAVIR ) AND CYCLOSPORIN IN A KIDNEY TRANSPLANT PATIENT WITH COVID-19 INFECTION
por: Then, R.F., et al.
Publicado: (2023)

Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient
por: Kwon, Eun-Jeong, et al.
Publicado: (2022)

Impact of extended-course oral nirmatrelvir/ritonavir (Paxlovid) in established Long COVID: Case series and research considerations
por: Cohen, Alison K., et al.
Publicado: (2023)

Paxlovid (Nirmatrelvir and Ritonavir) Use in Pregnant and Lactating Woman: Current Evidence and Practice Guidelines—A Scoping Review
por: Chourasia, Prabal, et al.
Publicado: (2023)

Risk Factors for In-Hospital Mortality from COVID-19 Among Nursing Home Patients—An Urban Center Experience
por: Vahia, Amit, et al.
Publicado: (2021)

Six-Month Post-Acute COVID-19: High Self-Reported Morbidity Among Adults Younger Than Sixty Years and Females
por: Bhargava, Ashish, et al.
Publicado: (2021)

Predictors for in-hospital mortality from coronavirus disease 2019 (COVID-19) infection among adults aged 18–65 years
por: Bhargava, Ashish, et al.
Publicado: (2020)

Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant
por: Young, Chelsea, et al.
Publicado: (2022)

The efficacy of Paxlovid against COVID-19 is the result of the tight molecular docking between M(pro) and antiviral drugs (nirmatrelvir and ritonavir)
por: Dawood, Ali Adel
Publicado: (2023)

523. Efficacy and Safety of Nirmatrelvir/Ritonavir for COVID-19 in Adolescents
por: Lee, Kiriam Escobar, et al.
Publicado: (2023)

483. Pharmacokinetics of Nirmatrelvir and Ritonavir in COVID-19 Patients with Hemodialysis
por: Li, Xin, et al.
Publicado: (2023)

Possible medication error risks with nirmatrelvir+ritonavir
Publicado: (2022)

Do risk factors at the time of hospital admission differ by sex for in-hospital mortality from coronavirus disease 2019 (COVID-19)?
por: Sharma, Mamta, et al.
Publicado: (2021)

Nirmatrelvir-ritonavir for COVID-19
por: McDonald, Emily G, et al.
Publicado: (2022)

Nirmatrelvir and ritonavir for COVID-19
Publicado: (2022)

Nirmatrelvir más ritonavir (Paxlovid) una potente combinación inhibidora de la proteasa 3CLpro del SARS-CoV-2
por: Reina, Jordi, et al.
Publicado: (2022)

Effect of Nirmatrelvir/Ritonavir (Paxlovid) on Hospitalization among Adults with COVID-19: an EHR-based Target Trial Emulation from N3C
por: Bhatia, Abhishek, et al.
Publicado: (2023)

786. Effect of Nirmatrelvir/Ritonavir versus Placebo on COVID-19─Related Hospitalizations and Other Medical Visits
por: Hammond, Jennifer, et al.
Publicado: (2022)

532. Nirmatrelvir/Ritonavir Versus Placebo in Unvaccinated and Vaccinated High Risk Patients
por: Leister-Tebbe, Heidi, et al.
Publicado: (2023)

1464. The Clinical Features of Pneumonia Caused by Legionella pneumophila vs. Streptococcus pneumoniae: A Retrospective Study
por: Salahie, Sima, et al.
Publicado: (2018)

636. Epidemiology and Outcome Among the Elderly Hospitalized Patients with Respiratory Syncytial Virus Infections
por: Bhargava, Ashish, et al.
Publicado: (2023)

Nirmatrelvir Plus Ritonavir: First Approval
por: Lamb, Yvette N.
Publicado: (2022)

2611. Risk Factors Associated with Longer Hospital Stay in Adult Patients with Respiratory Syncytial Virus Infections
por: Bhargava, Ashish, et al.
Publicado: (2023)

635. Morbidity and Mortality Associated with Respiratory Syncytial Virus Infections Among the Adult Hospitalized Patients
por: Bhargava, Ashish, et al.
Publicado: (2023)

2374. Predicting the Public Health Impact of Bivalent Vaccines and Nirmatrelvir-Ritonavir against COVID-19
por: Park, Hailey J, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_83v3q7mdqthk9bua7jomnu8cp8